Testing toripalimab after lung cancer surgery using ctDNA
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether a drug called toripalimab, given after lung cancer surgery, can help keep the cancer from coming back in people with early-stage non-small cell lung cancer. It uses a blood test (ctDNA) to look for leftover cancer cells and decide who might benefit most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had surgery to remove all visible lung cancer (clear margins) within the last 60 days.
- Your cancer stage must be IB, II, or some IIIA (non-small cell lung cancer).
- If your cancer is the non-squamous type, it must not have an EGFR or ALK gene change.
- You should be between 18 and 75 years old and able to do normal daily activities with little to no help (ECOG 0-1).
- Your blood counts, liver, and kidney function need to be within certain safe levels.
- You cannot have an active autoimmune disease, uncontrolled hepatitis B/C, or a history of other cancer in the last 5 years (with a few exceptions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the immunotherapy drug toripalimab to chemotherapy after surgery for non-small cell lung cancer (NSCLC). It is for patients who either had no treatment before surgery or had chemo-immunotherapy before surgery and still have signs of cancer in their lymph nodes. The goal is to see if this combination helps prevent cancer from coming back.
This trial tests whether giving an immunotherapy drug (toripalimab) before surgery can help people with a specific type of lung cancer (EGFR-mutated, PD-L1 positive) that can be removed. The goal is to see if it improves treatment results compared to surgery alone.
This trial is looking at whether using a sensitive blood test to find tiny bits of cancer left after surgery can help guide whether extra treatment is needed. The goal is to see if this approach is better than standard care for early-stage lung cancer patients.
This trial studies toripalimab to lower the risk of the cancer coming back after surgery and additional chemo-radiation. It may help the immune system “finish the job” after your main treatment, especially if you have higher-risk features.
This trial tests toripalimab (an immunotherapy) given before surgery for untreated head and neck squamous cell carcinoma, either alone or with chemotherapy. The goal is to shrink or control the cancer earlier and see if it improves outcomes for people who plan curative surgery.
This trial tests whether giving a drug called Toripalimab after surgery can help prevent early-stage non-squamous non-small cell lung cancer from coming back. It is for people whose tumors have high-risk features and PD-L1 levels of at least 1%.
Hear when a new Lung Cancer, Nonsmall Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.